Lenvatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LENVATINIB |
|---|---|
| Type | Drug |
| Aliases | KisplyxLenvimaЛенватиніб |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-ENDOMETRIAL DIS-RCC DIS-THYROID-PAPILLARY |
| Sources | SRC-AASLD-HCC-2023 SRC-NCCN-HCC-2025 |
Drug Facts
| Class | Multi-targeted oral TKI (VEGFR1-3, FGFR1-4, PDGFR-α, RET, KIT) |
|---|---|
| Mechanism | Broader VEGFR + FGFR inhibition vs sorafenib. REFLECT trial showed non-inferior OS and superior PFS/ORR in 1L unresectable HCC. |
| Typical dosing | >60 kg: 12 mg PO daily; ≤60 kg: 8 mg PO daily. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Hypertension pre-treatment optimization mandatory: ACE-i / ARB first, then add CCB (amlodipine), then beta-blocker if needed. Hold for SBP >160 or DBP >100 mm Hg; resume at lower dose once controlled. Child-Pugh A only fully studied; CP-B excluded from REFLECT (HCC) — limited data. SELECT (radioiodine-refractory DTC): mPFS 18.3 vs 3.6 mo placebo. CLEAR (RCC 1L): lenvatinib + pembrolizumab vs sunitinib — mPFS 23.9 vs 9.2 mo, OS HR 0.66. KEYNOTE-775 (R/R endometrial post-platinum): lenvatinib + pembro vs chemo, OS HR 0.62. Baseline + serial BP, urinalysis (UPCR), LFTs, TSH, ECG. Counsel hold pre- and post-elective surgery (≥2 wk wound-healing). UA: зареєстрований; НСЗУ покриває DTC, ГЦК, RCC, ендометрій (з pembro).
Used By
Regimens
REG-LENV-PEMBRO-RCC- Lenvatinib + pembrolizumab (RCC, 1L)REG-LENVATINIB-THYROID-RAI-REF- Lenvatinib monotherapy (RAI-refractory progressive PTC, 1L systemic)REG-PEMBRO-LENVATINIB-ENDOM- Pembrolizumab + Lenvatinib (KEYNOTE-775) — 2L pMMR endometrial